Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-XL antisense treatment

International Journal of Cancer

Volumn 106, Issue 2, 2003, Pages 160-166

  Hopkins Donaldson, Sally ^a   Cathomas, Richard ^a   Simões Wüst, A Paula ^a   Kurtz, Stefanie ^a   Belyanskya, Larisa ^a   Stahel, Rolf A ^a   Zangemeister Wittke, Uwe ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antisense; Apoptosis; Bcl 2 Bcl xL; Chemosensitization; Mesothelioma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE 4259; ANTISENSE OLIGONUCLEOTIDE 4625; CASPASE 3; CASPASE 7; CISPLATIN; ENZYME PRECURSOR; GEMCITABINE; MESSENGER RNA; PROCASPASE 7; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER THERAPY; CASPASE 3 LIKE ACTIVITY; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIZATION; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MESOTHELIOMA; MESOTHELIOMA CELL; MESOTHELIOMA ZL34; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CASPASES; CELL DIVISION; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DNA PRIMERS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIALS; MESOTHELIOMA; MITOCHONDRIA; OLIGONUCLEOTIDES, ANTISENSE; PLEURAL NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; RIBONUCLEOTIDE REDUCTASES; TUMOR CELLS, CULTURED;

EID: 0037817461     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11209     Document Type: Article

References (47)

1. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996;14:1007-17.
2. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53.
3. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63.
4. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17.
5. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992;52:2610-5.
6. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
7. Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002;29:82-96.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
9. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001;15:1022-32.
10. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998;16:395-419.
11. van Loo G, Saelens X, Van Gurp M, MacFarlane M, Martin SJ. Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 2002;9:1031-42.
12. Vander-Heiden MG, Chandel NS, Wiliamson EK, Schumacker PT, Thompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1998;91:627-37.
13. Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 1998;16:2265-82.
14. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12.
15. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
16. NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O'Loughlin C, Daly C, Nunez G, Scanlon KJ, Clynes M. Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int J Cancer 1999;82:368-76.
17. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002;97:584-92.
18. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 1999;5:3508-15.
19. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xL gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001;25:562-8.
20. Mohiuddin I, Cao X, Fang B, Nishizaki M, Smythe WR. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xL down-regulation in mesothelioma. Cancer Gene Ther 2001;8:547-54.
21. Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002;123:1191-8.
22. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol 1998;275:165-71.
23. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-4.
24. Koty PP, Zhang H, Levitt ML. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 1999;23:115-27.
25. Leech SH, Olie RA, Gautschi O, Simoes-Wust AP, Tschopp S, Haner R, Hall J, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int J Cancer 2000;86:570-6.
26. Simoes-Wust AP, Olie RA, Gautschi O, Leech SH, Haner R, Hall J, Fabbro D, Stahel RA, Zangemeister-Wittke U. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 2000;87:582-90.
27. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH, Natt F, Haner R, Martin P, Hall J, Nalin CM, Stahel RA. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000;6:2547-55.
28. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA, Zangemeister-Wittke U. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001;93:463-71.
29. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997;90:1208-16.
30. Gottschalk AR, Boise LH, Thompson CB, Quintans J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. PNAS 1994;91:7350-4.
31. Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA, Wyche JH. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res 1996;56:1621-8.
32. Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992;51:296-301.
33. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997;89:1027-36.
34. Ziegler A, Simoes-Wuest AP, Zangemeister-Wittke U. Optimizing the efficacy of antisense oligodeoxynucleotides targeting inhibitors of apoptosis. Methods Enzymol 1999;314:477-90.
35. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000;60:2805-9.
36. Olie RA, Durrieu F, Cornillon S, Loughran G, Gross J, Earnshaw WC, Golstein P. Apparent caspase independence of programmed cell death in Dictyostelium. Curr Biol 1998;8:955-8.
37. Segers K, Ramael M, Singh SK, Weyler J, Van Meerbeeck J, Vermeire P, Van Marck E. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 1994;424:631-4.
38. Olie R, Hafner C, Küttel R, Sigrist B, Willers J, Dummer R, Hall J, Stahel R, Zangemeister-Wittke U. Bcl-2 and bcl-xl antisense oligonucleotides induce apoptosis in malignant melanoma cells of different clinical stages. J Invest Dermatol 2002;118:505-12.
39. Shangary S, Johnson DE. Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry 2002;41:9485-95.
40. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 2002;29:62-9.
41. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000;60:7133-41.
42. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999;6:279-85.
43. Xu Z, Friess H, Solioz M, Aebi S, Korc M, Kleeff J, Buchler MW. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 2001;94:268-74.
44. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002;97:439-45.
45. Simoes-Wuest AP, Schürpf T, Hall J, Stahel RA, Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat, 2002;76:157-66.
46. Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 2001;25:111-8.
47. Ratto GB, Civalleri D, Esposito M, Spessa E, Alloisio A, De Cian F, Vannozzi MO. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999;117:759-65.